Manufacturing of bupivacaine multivesicular liposomes

US11311486B1 · US · B1

Patent metadata
FieldValue
Publication numberUS-11311486-B1
Application numberUS-202117536478-A
CountryUS
Kind codeB1
Filing dateNov 29, 2021
Priority dateJan 22, 2021
Publication dateApr 26, 2022
Grant dateApr 26, 2022

How to read this patent

A practical reading order for non-experts. Skip the full description unless you need deep technical detail.

  1. Title

    What the patent document calls the invention.

  2. Abstract

    A short plain-language summary of the technical disclosure.

  3. Assignees and inventors

    Who owns or filed the patent and who is credited as inventor.

  4. Key dates

    Filing, priority, publication, and grant dates set the timeline.

  5. First independent claim

    The legal scope of protection — read this for what is actually claimed.

  6. CPC / IPC classifications

    Technology tags used to group this patent with similar filings.

  7. Citations and related patents

    Prior art links and similar publications in this corpus.

Abstract

Official abstract text for this publication.

Embodiments of the present application relate to commercial manufacturing processes for making bupivacaine multivesicular liposomes (MVLs) using independently operating dual tangential flow filtration modules.

First claim

Opening claim text (preview).

What is claimed is: 1. A composition of bupivacaine encapsulated multivesicular liposomes (MVLs), comprising: bupivacaine encapsulated MVLs comprising bupivacaine residing inside a plurality of internal aqueous chambers of MVLs separated by lipid membranes, wherein the lipid membranes comprise 1,2-dierucoylphosphatidylcholine (DEPC), 1,2-dipalmitoyl-sn-glycero-3 phospho-rac-(1-glycerol) (DPPG), cholesterol, and at least one neutral lipid, the plurality of internal aqueous chambers of the MVLs also comprise lysine; and an aqueous medium in which the bupivacaine encapsulated MVLs are suspended, wherein the aqueous medium also comprises unencapsulated bupivacaine; wherein the bupivacaine concentration in the composition is from about 11.3 mg/mL to about 17.0 mg/mL, wherein an erucic acid concentration in the composition is about 53 μg/mL or less after the composition is stored at 25° C. for three months. 2. The composition of claim 1 , wherein the composition has a pH of about 6.9 after the composition is stored at 25° C. for three months. 3. The composition of claim 1 , wherein the erucic acid concentration in the composition is about 99 μg/mL or less after the composition is stored at 25° C. for six months. 4. The composition of claim 3 , wherein the composition has a pH of about 6.5 after the composition is stored at 25° C. for six months. 5. The composition of claim 3 , wherein the at least one neutral lipid in the lipid membranes comprises tricaprylin. 6. The composition of claim 3 , wherein the encapsulated lysine concentration in the bupivacaine encapsulated MVLs composition is about 0.03 μg/mL. 7. The composition of claim 3 , wherein the bupivacaine concentration in the composition is about 13.3 mg/mL. 8. The composition of claim 3 , wherein the DEPC and DPPG in the composition is in a mass ratio of about 7:1 to about 10:1. 9. The composition of claim 3 , wherein the percent packed particle volume (% PPV) of the bupivacaine encapsulated MVLs in the composition is about 32% to 44%. 10. The composition of claim 3 , wherein the bupivacaine is in a salt form. 11. The composition of claim 10 , wherein the bupivacaine is in the form of bupivacaine phosphate. 12. The composition of claim 1 , wherein the aqueous medium comprises a saline solution. 13. The composition of claim 3 , wherein the aqueous medium comprises a saline solution. 14. A method of treating or ameliorating pain in a subject in need thereof, comprising administering the composition of claim 3 to the subject. 15. The method of claim 14 , wherein the administration is via local infiltration to a surgical site to provide postsurgical local analgesia. 16. The method of claim 14 , wherein the administration is via interscalene brachial plexus nerve block or femoral nerve block to provide postsurgical regional analgesia. 17. The method of claim 14 , wherein the composition has a volume of 10 mL or 20 mL for a single-dose administration. 18. The method of claim 14 , wherein the composition has a pH of about 6.5 after the composition is stored at 25° C. for six months. 19. The method of claim 14 , wherein the at least one neutral lipid in the lipid membranes comprises tricaprylin. 20. The method of claim 14 , wherein the encapsulated lysine concentration in the bupivacaine encapsulated MVLs composition is about 0.03 μg/mL. 21. The method of claim 14 , wherein the bupivacaine concentration in the composition is about 13.3 mg/mL. 22. The method of claim 14 , wherein the DEPC and DPPG in the composition is in a mass ratio of about 7:1 to about 10:1. 23. The method of claim 14 , wherein the percent packed particle volume (% PPV) of the bupivacaine encapsulated MVLs in the composition is about 32% to 44%. 24. The method of claim 14 , wherein the bupivacaine is in a salt form. 25. The method of claim 24 , wherein the bupivacaine is in the form of bupivacaine phosphate. 26. The method of claim 14 , wherein the aqueous medium comprises a saline solution. 27. The method of claim 21 , wherein the encapsulated lysine concentration in the bupivacaine encapsulated MVLs composition is about 0.03 μg/mL. 28. The method of claim 21 , wherein the percent packed particle volume (% PPV) of the bupivacaine encapsulated MVLs in the composition is about 32% to 44%. 29. The method of claim 28 , wherein the bupivacaine is in a salt form. 30. The method of claim 29 , wherein the bupivacaine is in the form of bupivacaine phosphate. 31. The method of claim 30 , wherein the aqueous medium comprises a saline solution. 32. The method of claim 21 , wherein the administration is via local infiltration to a surgical site to provide postsurgical local analgesia. 33. The method of claim 21 , wherein the administration is via interscalene brachial plexus nerve block or femoral nerve block to provide postsurgical regional analgesia. 34. The method of claim 21 , wherein the composition has a volume of 10 mL or 20 mL for a single-dose administration.

Assignees

Inventors

Classifications

  • comprising multiple microfiltration steps · CPC title

  • A61K9/1277Primary

    Preparation processes; Proliposomes · CPC title

  • Diafiltration · CPC title

  • A61K31/451Primary

    having a carbocyclic group directly attached to the heterocyclic ring, e.g. glutethimide, meperidine, loperamide, phencyclidine, piminodine · CPC title

  • Cross-flow filtration · CPC title

Patent family

Related publications grouped by family.

External sources

Frequently asked questions

Answers are generated from the same data shown on this page.

What does patent US11311486B1 cover?
Embodiments of the present application relate to commercial manufacturing processes for making bupivacaine multivesicular liposomes (MVLs) using independently operating dual tangential flow filtration modules.
Who is the assignee on this patent?
Pacira Pharmaceuticals Inc
What technology area does this patent fall under?
Primary CPC classification A61K9/1277. Mapped technology areas include Human Necessities.
When was this patent published?
Publication date Tue Apr 26 2022 00:00:00 GMT+0000 (Coordinated Universal Time) (B1). Legal status and post-grant events are not shown on this page.
What related patents are in patentsdb?
We list 11 related publications on this page (citations in our corpus or others sharing the same primary CPC).